Business
Results of 2024 Annual General Meeting
Results of 2024 Annual General Meeting.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\n \nResults of 2024 Annual General Meeting\n \nLondon, UK, 20 June 2024: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anaemia), announces the voting results for each resolution set out in the Notice of Annual General Meeting 2024. The Board reports that all resolutions were passed: 1 to 10 passed as ordinary resolutions and 11 to 12 passed as special resolutions.\n \nThe following table shows the votes cast on each resolution:\n \n\n\n\n\n \n\n\nVOTES\nFOR\n\n\n%\n\n\nVOTES AGAINST\n\n\n%\n\n\nWITHHELD VOTES\n\n\n\n\nResolution 1\n\n\n371,135,672\n\n\n99.65%\n\n\n1,321,765\n\n\n0.35%\n\n\n387,002\n\n\n\n\nResolution 2\n\n\n367,256,140\n\n\n98.70%\n\n\n4,821,667\n\n\n1.30%\n\n\n766,632\n\n\n\n\nResolution 3\n\n\n368,781,407\n\n\n99.11%\n\n\n3,296,400\n\n\n0.89%\n\n\n766,632\n\n\n\n\nResolution 4\n\n\n368,781,161\n\n\n99.11%\n\n\n3,296,646\n\n\n0.89%\n\n\n766,632\n\n\n\n\nResolution 5\n\n\n369,852,377\n\n\n99.40%\n\n\n2,225,430\n\n\n0.60%\n\n\n766,632\n\n\n\n\nResolution 6\n\n\n369,852,377\n\n\n99.39%\n\n\n2,266,765\n\n\n0.61%\n\n\n725,297\n\n\n\n\nResolution 7\n\n\n368,193,486\n\n\n98.96%\n\n\n3,884,321\n\n\n1.04%\n\n\n766,632\n\n\n\n\nResolution 8\n\n\n371,077,210\n\n\n99.63%\n\n\n1,380,227\n\n\n0.37%\n\n\n387,002\n\n\n\n\nResolution 9\n\n\n370,260,710\n\n\n99.38%\n\n\n2,293,669\n\n\n0.62%\n\n\n290,060\n\n\n\n\nResolution 10\n\n\n368,304,167\n\n\n98.90%\n\n\n4,079,150\n\n\n1.10%\n\n\n461,122\n\n\n\n\nResolution 11\n\n\n368,067,995\n\n\n98.84%\n\n\n4,305,730\n\n\n1.16%\n\n\n470,714\n\n\n\n\nResolution 12\n\n\n367,071,290\n\n\n98.53%\n\n\n5,470,921\n\n\n1.47%\n\n\n302,228\n\n\n\n\n \nNotes:\n1. Number of shares in issue 782,056,367.\n2. Details of the votes received on the resolutions are available on the Company's website:\nhttps://www.shieldtherapeutics.com/corporate-documents/.\n3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.\n \nFor further information please contact:\n \n\n\n\n\nShield Therapeutics plc\...